Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Roxane Laboratories |
---|---|
Information provided by: | Roxane Laboratories |
ClinicalTrials.gov Identifier: | NCT00618059 |
The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine tablets, 7.5 mg, to SALAGEN® Tablets, 7.5 mg (MGI) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.
Condition | Intervention |
---|---|
Dry Mouth |
Drug: Pilocarpine |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Crossover Assignment, Bio-equivalence Study |
Official Title: | A Single Dose, Two-Period, Two-Treatment, 2-Sequence Crossover Bioequivalency Study of 7.5 mg Pilocarpine Tablets Under Fed Conditions |
Enrollment: | 28 |
Study Start Date: | August 2004 |
Study Completion Date: | August 2004 |
Primary Completion Date: | August 2004 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
CEDRA Clinical Research, LLC | |
Austin, Texas, United States, 78759 |
Principal Investigator: | Daniel V Freeland, DO | CEDRA Clinical Research, LLC |
Responsible Party: | Roxane Laboratories, Inc. ( Elizabeth Ernst, Director, Drug Regulatory Affairs and Medical Affairs ) |
Study ID Numbers: | PILO-04 |
Study First Received: | January 15, 2008 |
Last Updated: | February 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00618059 |
Health Authority: | United States: Institutional Review Board |
Malnutrition Pilocarpine Xerostomia |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Cholinergic Agonists Autonomic Agents Miotics |
Physiological Effects of Drugs Muscarinic Agonists Peripheral Nervous System Agents Cholinergic Agents Pharmacologic Actions |